NEXI · Neximmune, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | $0 | $0 | $0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $647.4K | $744.0K | - | $6.01M | $4.88M | $6.12M | - | $11.14M | $11.84M | $10.45M |
| SG&A | $2.08M | $2.01M | - | $3.99M | $2.90M | $3.70M | - | $3.72M | $4.09M | $4.60M |
| Total Operating Expenses | $3.51M | $2.76M | - | $10.00M | $7.78M | $9.83M | - | $14.86M | $15.93M | $15.05M |
| D&A | - | $114.9K | - | - | - | $263.8K | - | - | - | $227.0K |
| Operating Income | ($3.51M) | ($2.76M) | - | ($10.00M) | ($7.78M) | ($9.83M) | - | ($14.86M) | ($15.93M) | ($15.05M) |
| Interest Expense | - | - | - | - | - | - | - | $0 | $0 | $0 |
| Income Tax | $0 | $0 | - | $0 | $0 | $0 | - | $0 | $0 | $0 |
| Net Income | ($2.33M) | ($3.08M) | - | ($9.85M) | ($7.57M) | ($9.57M) | - | ($14.73M) | ($15.86M) | ($15.02M) |
| EPS - Basic | ($1.69) | ($2.46) | - | ($9.40) | ($7.25) | ($9.25) | - | ($15.00) | ($13.50) | ($16.50) |
| EPS - Diluted | ($1.69) | ($2.46) | - | ($9.40) | ($7.25) | ($9.25) | - | ($15.00) | ($17.25) | ($16.50) |
Balance Sheet
| Line item | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.42M | $4.45M | $3.20M | $9.00M | $16.28M | $22.32M | $34.64M | $45.86M | $40.64M | $24.50M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $1.28M | $771.6K | $1.34M | $737.5K | $582.5K | $650.6K | $2.38M | $1.26M | $1.65M | $2.01M |
| Current Assets | $3.13M | $6.04M | $5.40M | $10.32M | $18.50M | $25.40M | $37.37M | $52.00M | $59.59M | $71.90M |
| Total Assets | $5.86M | $8.99M | $8.59M | $14.56M | $23.47M | $30.66M | $43.06M | $57.67M | $65.67M | $78.31M |
| Current Liabilities | $4.74M | $4.63M | $5.08M | $6.20M | $6.27M | $6.79M | $10.33M | $9.39M | $9.11M | $7.09M |
| Long-term Debt | - | - | $0 | - | - | - | $0 | - | - | - |
| Total Liabilities | $4.94M | $6.02M | $5.08M | $6.31M | $6.47M | $7.09M | $10.76M | $9.96M | $9.81M | $7.92M |
| Stockholders' Equity | $696.4K | $2.74M | $3.51M | $8.25M | $17.00M | $23.58M | $32.30M | $47.72M | $55.85M | $70.39M |
| Retained Earnings | ($228.00M) | ($225.67M) | ($222.59M) | ($217.24M) | ($207.38M) | ($199.81M) | ($190.25M) | ($173.36M) | ($158.63M) | ($142.77M) |
Cash Flow
| Line item | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | ($2.42M) | - | - | - | ($12.28M) | - | - | - | ($16.48M) |
| Investing Cash Flow | - | $522.6K | - | - | - | ($42.7K) | - | - | - | $10.62M |
| Financing Cash Flow | - | $3.14M | - | - | - | $0 | - | - | - | $33.3K |
| CapEx | - | $0 | - | - | - | $42.7K | - | - | - | $344.4K |
| Free Cash Flow | - | ($2.42M) | - | - | - | ($12.33M) | - | - | - | ($16.82M) |
Ratios
| Metric | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | 0.79 | - | - | - | 1.29 | - | - | - | 1.12 |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -39.7% | -34.2% | - | -67.7% | -32.2% | -31.2% | - | -25.5% | -24.2% | -19.2% |
| Return on equity | -334.1% | -112.2% | - | -119.4% | -44.5% | -40.6% | - | -30.9% | -28.4% | -21.3% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.66 | 1.30 | 1.06 | 1.66 | 2.95 | 3.74 | 3.62 | 5.54 | 6.54 | 10.14 |
| Quick ratio | 0.66 | 1.30 | 1.06 | 1.66 | 2.95 | 3.74 | 3.62 | 5.54 | 6.54 | 10.14 |
| Cash ratio | 0.51 | 0.96 | 0.63 | 1.45 | 2.60 | 3.29 | 3.35 | 4.88 | 4.46 | 3.46 |
| Leverage | ||||||||||
| Debt / Equity | - | - | 0.00 | - | - | - | 0.00 | - | - | - |
| Debt / Assets | - | - | 0.00 | - | - | - | 0.00 | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 8.42 | 3.28 | 2.45 | 1.76 | 1.38 | 1.30 | 1.33 | 1.21 | 1.18 | 1.11 |
| Liabilities / Assets | 0.84 | 0.67 | 0.59 | 0.43 | 0.28 | 0.23 | 0.25 | 0.17 | 0.15 | 0.10 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | 0.00 | 0.00 | 0.00 |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 5.5x | 2.6x | - | 0.7x | 10.8x | 10.5x | - | 7.1x | 16.3x | 34.1x |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 54.9% | 71.9% | - | 32.7% | 51.1% | 34.7% | - | 4.1% | -30.9% | -136.7% |
| Net income growth (YoY) | 69.2% | 67.8% | - | 33.1% | 52.3% | 36.3% | - | -0.6% | -128.9% | -137.9% |
| EPS growth (YoY) | 76.7% | 73.4% | - | 37.3% | 58.0% | 43.9% | - | -99.5% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | 80.4% | - | - | - | 26.7% | - | - | - | -149.1% |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -95.9% | -88.4% | -89.1% | -82.7% | -69.6% | -66.5% | -61.4% | -50.9% | - | - |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing NexImmune against the 5 most active filers in the same SIC group.